Overview

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

Status:
Recruiting
Trial end date:
2025-08-14
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Collaborator:
Medicines for Malaria Venture